Krystal Biotech (KRYS) Equity Average (2017 - 2026)

Krystal Biotech has disclosed Equity Average across 10 years of filings, most recently posting $1.2 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $1.2 billion, up 29.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 29.27% YoY), and the FY2025 annual result was $1.1 billion, up 25.56% from the prior year.
• Equity Average came in at $1.2 billion for Q1 2026 at Krystal Biotech, up from $1.2 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.2 billion in Q1 2026 to a low of $505.9 million in Q1 2023.
• The 5-year median for Equity Average is $788.9 million (2024), against an average of $802.1 million.
• Across the five-year window, Equity Average surged 58.03% in 2022 and declined 11.41% in 2023, its largest moves.
• Krystal Biotech's Equity Average stood at $531.5 million in 2022, then jumped by 44.36% to $767.3 million in 2023, then grew by 19.4% to $916.1 million in 2024, then grew by 28.67% to $1.2 billion in 2025, then increased by 5.89% to $1.2 billion in 2026.
• The last three Equity Average figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.